Fujifilm has acquired a large-scale biologics site near Copenhagen, Denmark.
The company paid $890 million in cash for the former Biogen-owned campus, which consists of a manufacturing facility with six 15,000L bioreactors capable of churning out cell culture-derived biologics for clinical and commercial use. The campus also includes facilities for packaging and labeling, quality control, assembly, labs and warehouses.
Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm and a CDMO that specializes in biologics and advanced therapies, now owns four manufacturing sites. About 800 employees work at the new Danish site.
Read the press release.